Chemotherapy of anthracy-clineand taxan-resistant breast cancer
- Authors: Kovalenko E.I1, Satirova E.F1, Artamonova E.V1, Manzyuk L.V1
-
Affiliations:
- Issue: No 18 (2012)
- Pages: 28-32
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279996
- ID: 279996
Cite item
Open Access
Access granted
Abstract
The article presents the results of evaluation of effectiveness and safety of chemotherapy with capecitabine (Xeloda) as monotherapy or as a component of drug combinations, and assessment of progression-free survival in 83 patients with metastatic breast cancer (MBC). The study confirmed the high efficiency and sufficient tolerance of Xeloda and its combinations in anthracycline-resistant and anthracycline-taxan-resistant MBC patients. This drug can be recommended for extensive use in this unfavorable group of patients.
Full Text
References
- Blum J.L, et al. Capecitabine (Xeloda) in 162 patients wirh paclitaxel-pretreated MBC: updated results and analisis of dose madification. J Clin Oncol 1999;17:485.
- Blum J.L., et al. A multicenter phase II trial of Xeloda in taxane-refractory metastatic breast cancer. Cancer 2001;92:1759-68.
- Gilabert M., et al. Capecitabine after antracycline and taxane Exposure in HER2-negative metastatic breast cancer patients: Response, Survival and Prognostic Factors. QAnticancer Research March 2011;31(3):1079-86.
- Girre V., et al. Vinorelbine-5-fluorouracil combination as second line chemotherapy in metastatic breast cancer after anthracycline-taxane combination (AT). Annals of Oncology 2000;11 (Suppl. 4):24.
- Pallis A., et al. A multicenter randomizedphase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline-and taxane-pretreated women with metastatic breast cancer. Annals of Oncology 2011;10:1093.
- Reichardt P., et al. Capecitabine: The news standart in metastatic breast cancer failing antracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial. Eur J Cancer 2001;37(Suppl. 6):S191, abstr.699.
- Reichardt P. et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Annals of Oncology 2003;14: 1227-33.
- Fumoleau P. et al. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC) previously treated with antracyclines and taxanes: results of a large phase II study. Proc Am Soc Clin Oncol 2002;21:62a, abstr.247.
Supplementary files
